12th State of Georgia Lymphedema Awareness Program
..
Tags: lymphedema advocacy, lymphedema awareness, lymphedema conference, lymphedema information, lymphedema meeting, patient support
![]() | You are viewing Log in Create a LiveJournal Account Learn more | Explore LJ: Life Entertainment Music Culture News & Politics Technology |
lymphedemahomeRecent Entries | ||||
|
You are viewing the most recent 20 entries October 17th, 2009: 12th State of Georgia Lymphedema Awareness Program 12th State of Georgia Lymphedema Awareness Program . . THERE IS STILL TIME TO GET THOSE REGISTRATIONS IN . An educational and awareness conference for patients, caregivers and professionals! . Where? . Saint Joseph Hospital Auditorium 5665 Peachtree Dunwoody Road, NE Atlanta, GA 30342 . When? . Saturday, October 24, 2009 7:30 am - 5:00 pm . . Schedule . 7:30-8:15am Registration – Continental Breakfast – Exhibits 8:15-8:30am Welcome .. Plenary Session: . 8:30-10:00am Moderator: Elaine Gunter, MT (ASCP) . Nicole Stout, PT, MPT, CLT-LANA Will discuss her studies on early intervention for breast cancer including the anatomy, reconstruction, breast cancer surgeries, truncal and other upper extremity lymphedema . 10:00-10:30am Break Exhibits . 10:30-12:00 Charles McGarvey, PT, DPT, MS, FAPTA . Lymphedema Secondary to Pelvic Cancer Treatment: A Review of Literature and Clinical Practice . 12:00 – 1:30pm Lunch Exhibits . 1:00-2:15pm Teen (only) Networking -Parent Networking (parents of children with lymphedema) . Separate sessions . Plenary Session: . 1:30-2:15pm Daniel Beless, MD, Director of Wound Care at Saint Joseph Hospital Wound Care and the lymphedema patient . 2:15-3:00pm DeCourcy Squire, PT, CLT-LANA Research updates from the International Society of Lymphology of Lymphedema Diagnosis and Treatment . 3:00-3:30pm Break Exhibits . 3:30-4:30pm Panel Discussion All speakers will participate in this question and answer discussion . 4:30-5:00pm Closing Remarks Tags: lymphedema advocacy, lymphedema awareness, lymphedema conference, lymphedema information, lymphedema meeting, patient support September 29th, 2009: Lighthouse Lymphedema Network I wanted to make a special announcement that the Lighthouse Lymphedema Network is now on Facebook. You can join by going to: http://www.facebook.com/group.php?gid=16 There is also an area where you can post and participate. AND - don't forget our upcoming program in October. We will be having both a parenting network and a teen network this year....be there or be square! see the details for that at: Lighthouse Lymphedema Network http://www.lymphedemalighthouse.org/ **yes, I'm on it too :-) Pat Tags: atlanta, facebook, georgia, lighthouse lymphedema network, lymphedema awareness, lymphedema program September 11th, 2009: Georgia Lymphedema Education and Awareness Program 11th Annual Lymphedema Education & Awareness Program An educational and awareness conference for patients, caregivers and professionals! Where? Piedmont Hospital Piedmont Hospital Richard H. Rich Auditorium 1968 Peachtree Road, NW, Building 77 Atlanta, Georgia When?Saturday, October 18, 20087:30 am - 5:30 pm Program includes What to expect of tissue after radiation? What is the physiology response of radiation? What does radiation do to the lymph nodes? - Peter Rossi, MD How does vascular flow affect the lymphatics? - Ken Harper, MD Expectations of surgery. - Christopher Hart, MD, FACSThe Lymphatic System, Wound Care, Infections and Treatment - Paula Stewart, MDParent Networking Aquatic Exercises The Connection of obesity and increased swelling in people with lymphedema and lipedema.and more. Additional information and registration form - Home website - Lighthouse Lymphedema Network See you there - Pat
Tags: lymphedema advocacy, lymphedema awareness, lymphedema education, lymphedema information May 23rd, 2009: Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional as *Editor's note: Here is yet another article relating to the use of debulking surgeries for lymphedema. I am still in disbelief that this surgery is being used in the 21st century. The followup time frame noted is 27.3 months. This is ridiculous as 2 years after my surgeries, I was still doing good. There were no complications and the swelling was diminshed. Longer term follow-ups would reveal this hidden dangers and eventual complications of this procedure. The doctors did no favors for these patients. In reality, they have sentanced them to severe complications years down the road. Please, please dear reader before anyone talks you into this surgery read carefully my article relating to it: Complications of Lymphedema Debulking Surgery http://www.lymphedemapeople.com/phpBB3/v Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional assessment. Ann Plast Surg. 2009 Jun van der Walt JC, Perks TJ, Zeeman BJ, Bruce-Chwatt AJ, Graewe FR. Department of Plastic and Reconstructive Surgery, Tygerberg Hospital/ University of Stellenbosch, Francie van Zijl Drive, Parow, Private Bag X3, South Africa. chrisenkate@mweb.co.za Tags: modified charles procedure; leg lymphede November 28th, 2008: Localized lymphedema (elephantiasis): a case series and review of the literature Localized lymphedema (elephantiasis): a case series and review of the literature by: Song Lu, Tien A Tran, David M Jones, Dale R Meyer, Jeffrey S Ross, Hugh A Fisher, John A Carlson Journal of Cutaneous Pathology, Vol. 9999, No. 9999. (2008) Background: Lymphedema typically affects a whole limb. Rarely, lymphedema can present as a circumscribed plaque or an isolated skin tumor. Objective: To describe the clinical and pathologic characteristics and etiologic factors of localized lymphedema. Methods: Case2013control study of skin biopsy and excision specimens histologically diagnosed with lymphedema and presenting as a localized skin tumor identified during a 4-year period.Results: We identified 24 cases of localized lymphedema presenting as solitary large polyps (11), solid or papillomatous plaques (7), pendulous swellings (4), or tumors mimicking sarcoma (2). Patients were 18 females and 6 males with a mean age of 41 years (range 16201374). Anogenital involvement was most frequent (75%) 2013 mostly vulva (58%), followed by eyelid (13%), thigh (8%) and breast (4%). Causative factors included injury due to trauma, surgery or childbirth (54%), chronic inflammatory disease (rosacea, Crohn's disease) (8%), and bacterial cellulitis (12%). Eighty-five percent of these patients were either overweight (50%) or obese (35%). Compared with a series of 80 patients with diffuse lymphedema, localized lymphedema patients were significantly younger (41 vs. 62 years old, p = 0.0001), had no history of cancer treatment (0% vs. 18%, p = 0.03), and had an injury to the affected site (54% vs. 6%, p = 0.0001). Histologically, all cases exhibited dermal edema, fibroplasia, dilated lymphatic vessels, uniformly distributed stromal cells and varying degrees of papillated epidermal hyperplasia, inflammatory infiltrates and hyperkeratosis. Tumor size significantly and positively correlated with history of cellulitis, obesity, dense inflammatory infiltrates containing abundant plasma cells, and lymphoid follicles (p < 0.05). A history of cellulitis, morbid obesity, lymphoid follicles and follicular cysts predicted recurrent or progressive swelling despite excision (p < 0.05). Conclusions: Localized lymphedema should be considered in the etiology of skin tumors when assessing a polyp, plaque, swelling or mass showing dermal edema, fibrosis and dilated lymphatics on biopsy. A combination of lymph stasis promoting factors (trauma, obesity, infection and/or inflammatory disorders) produces localized elephantiasis. Tags: bacterial cellulitis, chronic inflammatory disease, crohn's disease, dermal edema, dilated lymphatic vessels, elephantiasis, fibroplasia, localized lymphedema, lymphoid follicles, morbid obesity, rosacea, skin biopsy, skin tumor :
Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. Hum Genet. 2008 Nov 12. Connell FC, Ostergaard P, Carver C, Brice G, Williams N, Mansour S, Mortimer PS, Jeffery S; Lymphoedema Consortium. Medical Genetics Unit, Clinical Developmental Sciences, St Georges University of London, Cranmer Terrace, London, SW17 0RE, UK. Milroy disease (hereditary lymphoedema type I, MIM 153100) is a congenital onset primary lymphoedema with autosomal dominant inheritance. Mutations in the gene, vascular endothelial growth factor receptor 3, VEGFR3 (FLT4), are known to cause Milroy disease, but there is uncertainty about the prevalence of VEGFR3 mutations in patients with primary lymphoedema and more specifically in those with a phenotype that resembles Milroy disease. This study aims to address this issue and thereby delineate the Milroy disease phenotype. Fifty-two patients with primary lymphoedema were analysed for mutations in the coding regions of VEGFR3. Patients were divided into four groups: Typical Milroy disease with family history (group I), typical Milroy disease with no family history (group II), atypical Milroy disease (group III), and complex primary lymphoedema (group IV). Results demonstrated that with rigorous phenotyping the likelihood of detecting VEGFR3 mutations is optimised. Mutation prevalence is 75% in typical Milroy patients with a family history (group I) and 68% if positive family history is not a diagnostic criterion. A positive family history is not essential in Milroy disease. The likelihood of detecting VEGFR3 mutations in patients who have a phenotype which is not typical of Milroy disease is very small (<5%). For the 22 mutation positive patients, 14 novel VEGFR3 mutations were identified, two of which were in exon 22 and one in exon 17, confirming that these exons should be included in VEGFR3 analysis. No mutations were found outside the kinase domains, showing that analysis of this part of the gene is not useful for Milroy disease patients. VEGFC, which encodes the ligand for VEGFR3, was sequenced in all patients with typical Milroy disease (groups I and II) and no mutations were identified. November 25th, 2008: Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphedemas. Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas. Hum Genet. 2008 Nov 12. Connell FC, Ostergaard P, Carver C, Brice G, Williams N, Mansour S, Mortimer PS, Jeffery S; Lymphoedema Consortium. Medical Genetics Unit, Clinical Developmental Sciences, St Georges University of London, Cranmer Terrace, London, SW17 0RE, UK. Milroy disease (hereditary lymphoedema type I, MIM 153100) is a congenital onset primary lymphoedema with autosomal dominant inheritance. Mutations in the gene, vascular endothelial growth factor receptor 3, VEGFR3 (FLT4), are known to cause Milroy disease, but there is uncertainty about the prevalence of VEGFR3 mutations in patients with primary lymphoedema and more specifically in those with a phenotype that resembles Milroy disease. This study aims to address this issue and thereby delineate the Milroy disease phenotype. Fifty-two patients with primary lymphoedema were analysed for mutations in the coding regions of VEGFR3. Patients were divided into four groups: Typical Milroy disease with family history (group I), typical Milroy disease with no family history (group II), atypical Milroy disease (group III), and complex primary lymphoedema (group IV). Results demonstrated that with rigorous phenotyping the likelihood of detecting VEGFR3 mutations is optimised. Mutation prevalence is 75% in typical Milroy patients with a family history (group I) and 68% if positive family history is not a diagnostic criterion. A positive family history is not essential in Milroy disease. The likelihood of detecting VEGFR3 mutations in patients who have a phenotype which is not typical of Milroy disease is very small (<5%). For the 22 mutation positive patients, 14 novel VEGFR3 mutations were identified, two of which were in exon 22 and one in exon 17, confirming that these exons should be included in VEGFR3 analysis. No mutations were found outside the kinase domains, showing that analysis of this part of the gene is not useful for Milroy disease patients. VEGFC, which encodes the ligand for VEGFR3, was sequenced in all patients with typical Milroy disease (groups I and II) and no mutations were identified. Tags: congenital, flt4, hereditary lymphedema, milroy disease, milroy syndrome, primary lymphedema, type i, vegfr3 November 10th, 2008: Pat O'Connor Medical Blogs and Online Support Groups Good Morning Everyone This is about journeying through life with a medical condition called ***Our Family of On Line Support Groups*** Our frontline online support group for lymphedema. Provides community, support, information and advocacy on behalf of patients from all corners of the globe. A very special support group for children who have lymphedema and their parents. Tremendous source of community, support and information on the day to day care of children with the condition. Support group for men who have lymphedema. Brotherhood, comradere, support and information - a safe place to let the hair down and ask questions and interact. A special group for teenagers who face difficult issues during their teen years in how to cope with, live with and most important to learn how to live a rich and rewarding life despite having lymphedema Support group for parents, patients, children who suffer from all forms of lymphangiectasia. This condition is caused by dilation of the lymphatics. It can affect the intestinal tract, lungs and other critical body areas. Works inconjunction with our Xanga blog Lymphangiectasia
Millions of people are afflicted with this almost totally misunderstood and frustrating medical condition. Articles relating to living with lipedema, treatments and other peeer reviewed information. Works in conjunction with our online support group Lipedema Works in conjunction with our blogs on Disorders of the Lymph System and Developemental Disorders of the lymph system. All lymphatic conditions included with special emphasis on lymphatic malformations, lymphangiomas, cystic hygromas, Castleman's Disease All About Lymphoedema – Australia Support group for our friends down under with lymphedema. Provides a great sources of information, community and support. Our frontline Google support group for lymphedema. Information, support, community and help. A leader in providing peer reviewed research studies and abstracts on lymphedema.
Our online support group for the UK. Accross the pond group for information, support and community for those with lymphoedema. http://groups.msn.com/LetsTalkLymphedema Tags: antibiotics, bacterial infections, burkitts lymphoma, castleman's disease, celllulitis, cutaneous lymphoma, cystic hygromas, fungal infection, kaposi's sarcoma, leg lymphedema, lipedema, lymphangiectasia, lymphangiomas, lymphatic disorders, lymphatic malformations, lymphedema, lymphoma, merkel cell cancer, mrsa, trisomy disorders November 4th, 2008: Patient Strategies Identified For Managing Symptoms Of Lymphedema Patient Strategies Identified For Managing Symptoms Of Lymphedema Article Date: 30 Oct 2008 - 4:00 PDT An estimated 2 million women in the United States are at risk of developing lymphedema, a condition that involves the chronic and abnormal swelling of the arm, chest, neck and/or back, as a complication of breast cancer treatment. While physicians will recommend proven techniques to manage the swelling, a University of Missouri researcher has found that patients often won't follow the recommendations, or they will use alternative treatments and not discuss them with their doctors. "Lymphedema has a profound impact on health and well-being, but often goes undiagnosed and untreated by physicians and patients," said Jane Armer, professor in the Sinclair School of Nursing and director of nursing research at the Ellis Fischel Cancer Center. "Understanding the ways that people self-manage the chronic symptoms of lymphedema is essential to facilitate an improvement in the use of treatments and the quality of life of these people." Armer surveyed breast cancer survivors with lymphedema about their practices for managing symptoms, including swelling and heaviness. She found the most common strategy was to not treat the symptom. For 12 out of 14 symptoms, patients reported taking no action 29 percent to 65 percent of the time. This finding is consistent with Armer's conclusions from a previous study. "Considering the entire lymphedema population (not just breast cancer survivors), the percentage of patients who treat their symptoms is probably even lower," Armer said. "Data have shown that breast cancer survivors are more proactive in seeking information for self-care, and they are more likely to follow a daily self-care plan for lymphedema than those who developed lymphedema for a different reason." Armer found that patients who choose to treat their symptoms use a variety of techniques, which can be divided into three main groups. The first group includes recommended management techniques, non-pharmaceutical strategies typically recommended by physicians, including manual lymphatic drainage, compression garments and elevation. Patients use these techniques most often, or 47 percent of the time. The second group was pharmaceutical treatments including the use of medications both prescription (antibiotics) and over-the-counter (pain medication and cortisone cream). The final group was lay symptom management techniques, strategies not necessarily recommended by health care professionals but common sense, folk, complementary or alternative methods. According to Armer, patients increasingly are using lay therapies, but less than 40 percent report discussing their use of complementary therapies with a doctor. Previous research has found these unconventional therapies are generally not taught at medical schools or are unavailable at most hospitals. "While lay symptom management is undoubtedly an important form of health care, the discrepancy between the use of self-care treatments and doctor-recommended treatments for lymphedema must be addressed," Armer said. "It's important for health care professionals to recognize the scope and diversity of practices that breast cancer survivors choose when managing their symptoms. Continued research of this issue can help develop effective management techniques to be incorporated into standards of practice for physicians and patients." The Lymphedema Research Project at Ellis Fischel and Sinclair School of Nursing provides research opportunities for breast cancer survivors to participate in oncology nursing research. The studies are funded by the Lance Armstrong Foundation and the National Institutes of Health. MU researchers maintain a database of participants for future studies; interested participants for breast cancer and/or lymphedema research may submit their contact information and will be contacted if they meet the criteria for current or new studies. Friends, family members and co-workers who have not had breast cancer or lymphedema also may enroll for studies that require matched control participants. "We are experiencing great success by connecting participants to studies through our database. It gives people an opportunity to contribute to breast cancer research and allows our research efforts to continue," Armer said. "A critical next step in lymphedema research is the rigorous evaluation of the effectiveness of self-management techniques." Source: Emily Smith University of Missouri-Columbia Tags: arm swelling, cancer, compression garments, leg swelling, lymphedema, lymphedema self care, management, manual lymphatic drainage, patients, pharmaceutical treatment, treatment October 27th, 2008: The psychosocial effects of cancer-related lymphedema. Hi Friends, visitors and members. First just wanted to say my health has caused me to take a most unwanted vacation from being online for a couple months. I had some frustrating setbacks with lymphedema, lung fluid and the like. But, I'm back and will continue posting new atsracts and info. I found the one below interesting and a bit heopful as maybe this represents a "glint" of increasing interest in us at lymphedema patients and in the whole spectrum of how lymphedema effects our daily/moment to moment life. Pat The psychosocial effects of cancer-related lymphedema. J Palliat Care. 2008 Autumn Towers A, Carnevale FA, Baker ME. Palliative Care Division, McGill University, Montreal, Quebec, Canada. Life-long lymphedema is a common complication of cancer therapy. In this Canadian study, we adopted a phenomenological methodology to explore the experience of patients with cancer-related lymphedema, and their spouses. We conducted audio taped semistructured interviews with 11 patients and eight spouses, who were recruited through a university hospital-based lymphedema clinic and through local lymphedema therapists. We developed an analytical framework from the data themselves, and tentative hypotheses and thematic categories that represented shared case features. Participants expressed frustration because of lack of financial support from government and insurance companies, inadequate knowledge and perceived lack of interest on the part of physicians, and lack of awareness in society in general. This study suggests further investigation of the funding of lymphedema treatments, and of the effect of lymphedema on work, intimacy, and leisure activities. Our research findings will inform educational initiatives and cancer rehabilitation programs. PubMedTags: lymphedema; cancer therapy; insurance co August 24th, 2008: Lymphedema People Lymphedema People Public Notice Statement of Ownership The website Lymphedema People also referred hereafter as The website Lymphedema People (commonly referred to as Ads placed on the website and donations are the responsibility of the domain and are to be used to provide financial reimbursement to the domain for the expenses it incurs as hosting the website. Responsibility for those ads and questions concerning the ads rests with the domain and not the website. Users of the website agree to a hold harmless agreement regarding the ads and donations. Under the terms of intellectual property, established by legal precedent and law, the website Lymphedema People The website name Lymphedema People both as a trademark and a website name is the sole property of Pat O’Connor. Use of that name is prohibited by any other agency, person group or entity. All online support groups, blogs and entities so identified as being sponsored by Lymphedema People are the sole personal property of Pat O’Connor and are governed by the hosting agency. These agencies include, but are not restricted to Yahoo, Google, AOL, Lycos and MSN. These groups are listed as sponsored as defined by the website Lymphedema People and not the domain. Pat O’Connor August 14, 2008
Tags: lymphedema people; ownership; intellectu August 12th, 2008: Breast cancer-related lymphoedema risk reduction advice: A challenge for health professionals. Breast cancer-related lymphoedema risk reduction advice: A challenge for health professionals. Cancer Treat Rev. 2008 Aug Nielsen I, Gordon S, Selby A. Discipline of Physiotherapy, James Cook University, Townsville, QLD 4811, Australia. Breast cancer-related lymphoedema (BCRL) is a debilitating, distressing condition affecting approximately one in five breast cancer survivors (Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study (editor's note: new research revises this to 35-40% of survivors). QJM 2005;98:343-8). The evidence-base for breast cancer-related lymphoedema risk reduction advice is scant and contradictory, with most studies in the area limited by small numbers, retrospective design and other methodological inadequacies. Current advice has the capacity to profoundly alter quality of life following treatment for breast cancer. Health professionals should review the risk reduction advice they provide to reflect the current understanding of aetiology and risk factors. Further research is required to provide more evidence for the content, to identify optimal methods of precautionary education delivery and to determine the effect of the advice on the patient's quality of life and perception of recovery. Tags: breast cancer-related lymphedema; bcrl; August 4th, 2008: Effects of complex decongestive physiotherapy on edema and quality of life of lower limb lymphedema Effects of complex decongestive physiotherapy on the oedema and the quality of life of lower unilateral lymphoedema following treatment for gynecological cancer. Kim SJ, Park YD. Department of Physical Therapy, Youngdong University, Chungbuk, Republic of Korea. There is increasing interest in the health-related quality of life (QOL) of patients with chronic lymphoedema. The purpose of the present study was to ascertain whether or not complex decongestive physiotherapy (CDP) for 57 gynecological cancer patients with unilateral lymphedema results in a measurable change in the oedema and QOL, and % excess volume correlated with change in QOL. % excess volume was significantly (P < 0.05) decreased after CDP. The QOL scores were significantly (P < 0.05) higher than the scores at baseline, indicating an improvement in the QOL. The change in % excess volume was associated with a change in physical functioning, social functioning, role-physical, bodily pain and general health at baseline and 1 month (P < 0.05). This study suggests that significant improvements are made in the QOL of gynecological cancer patients with unilateral lymphoedema after CDP, which is necessarily correlated with limb reduction. PMID: 18637114 [PubMed - as supplied by publisher] Tags: complex decongestive physiotherapy; leg July 26th, 2008: Meet the Therapist – new forum on Lymphedema People Meet the Therapist – new forum on Lymphedema People Have you ever needed to or wished that you could ask a therapist a quickie question about your treatment program, bandaging tips,garment problems? Well, now you can!!!! Announcing our new forum: MEET THE THERAPIST Managed by Tom Kinchloe, Certified Lymphedema Therapist Go to: Lymphedema People http://www.lymphedemapeople.com/ Click on: Forums Scroll down until you see the forum - and ask away :-) If any of our membes are also therapists, you are most welcome to join in and help. Tom is a member of our Yahoo group: Advocates for Lymphedema not only is he a top notch lymphedema therapist, but has a caring and compassionent heart for those he serves. I am very excited about this new forum and look forward to seeing everyone's participation. A half million people have visited Lymphedema People so far in 2008, come and be a part of the most popular website in the world for lymphedema and lymphatic conditions. Pat O’Connor Tags: arm lymphedema, leg lymphedema, lymphedema, lymphedema forum, lymphedema therapist, support group July 17th, 2008: Advocates for Lymphedema ======================================== Join us as we work for lymphedema patients everywhere: Advocates for Lymphedema Dedicated to be an advocacy group for lymphedema patients. Working towards education, legal reform, changing insurance practices, promoting research, reaching for a cure. http://health.groups.yahoo.com/group/Adv To Subscribe
Patt O'Connor Lymphedema People / Advocates for Lymphedema ======================================== Tags: advocates for lymphedema, law, lobbying, lymphedema, political action, suport group : 11th Annual Georgia Lymphedema Education & Awareness Program 11th Annual Lymphedema Education & Awareness Program Tags: lighthouse lymhpedema network, lymphedema, lymphedema information, patient education, seminar July 13th, 2008: Survey of Doppler use in lymphoedema practitioners in the UK. Survey of Doppler use in lymphoedema practitioners in the UK. Br J Community Nurs. 2008 Apr Todd M, Welsh J, Key M, Rice M, Adam J. Specialist Lymphoedema Service Glasgow. marie.todd@ggc.scot.nhs.uk PMID: 18595307 [PubMed - in process] Tags: doppler, lymphedema, lymphoedema, vascular assessment : Important changes on Lymphedema People Important changes on Lymphedema People I did want to advise everyone on some important changes on Lymphedema People. That takes you to a page where at the top in a yellow background panel you can subscribe to that page. Click on Tags: lymphedema, lymphedema people; June 27th, 2008: The clinical spectrum of lymphatic disease. The clinical spectrum of lymphatic disease. Ann N Y Acad Sci. 2008 Radhakrishnan K, Rockson SG. Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94306, USA. Address for correspondence: Stanley G. Rockson, M.D., Division of Cardiovascular Medicine, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA 94306. Voice: +1-650-725-7571; fax: +1-650-725-1599. srockson@cvmed.stanford.edu Lymphatic disease is quite prevalent, and often not well clinically characterized. Beyond lymphedema, there is a broad array of human disease that directly or indirectly alters lymphatic structure and function. The symptomatic and objective presentation of these patients can be quite diverse. In this review, we have attempted to provide a systematic overview of the subjective and objective spectrum of lymphatic disease, with consideration of all of the categories of disease that primarily or secondarily impair the functional integrity of the lymphatic system. Lymphedema is discussed, along with chromosomal disorders, lymphangioma, infectious diseases, lymphangioleiomyomatosis, lipedema, heritable genetic disorders, complex vascular malformations, protein-losing enteropathy, and intestinal lymphangiectasia. Tags: lympheatic disease; lymphedema; trisomy : Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymp Effect of vascular endothelial growth factor C (VEGF-C) gene transfer in rat model of secondary lymphedema. Vascul Pharmacol. 2008 May Liu Y, Fang Y, Dong P, Gao J, Liu R, Tian H, Ding Z, Bi Y, Liu Z. Department of Anatomy, Shandong University School of Medicine, Jinan, Shandong, 250012, PR China. Secondary lymphedema has been clinically well described, but a cure is still lacking. Although there have been previous investigations using plasmid DNA for gene therapy, few have focused on the use for the treatment of lymphedema. Therefore, we investigated the effects of VEGF-C gene transfer for the treatment of lymphedema using our plasmid pcDNA3.1-VEGF-C. We produced a surgical model of secondary lymphedema in the rat hindlimb and treated with local intradermal VEGF-C transfection to investigate the efficacy of gene transfer. Magnetic resonance imaging (MRI) (P less then 0.05), B ultrasound (P less then 0.05), and water displacement volumetry (P less then0.05) demonstrated a reduction of lymphedema in therapy group as compared to controls. Histological and immunofluorescent studies demonstrated numerous newly formed lymphatic vessels in therapy group. Our results indicate that VEGF-C gene therapy has produced new lymphatic vessels which may have improved functional lymphatic drainage to reduce lymphedema volume in our model. Abbreviations: VEGF, Effect of Vascular endothelial growth factor; MRI, Magnetic resonance imaging; VEGFR, Effect of Vascular endothelial growth factor receptor; HE, hematoxylin and eosin. Elsevier ScienceDirect
Keywords: VEGF-C; Rat; Secondary lymphedema Tags: vegf-c; rat; secondary lymphedema;mri; m |
|||